Onconova Therapeutics
ONTX
#8020
Rank
$20.9 M
Marketcap
$1.00
Share price
-0.47%
Change (1 day)
-8.69%
Change (1 year)

P/E ratio for Onconova Therapeutics (ONTX)

P/E ratio as of May 2024 (TTM): -0.9953

According to Onconova Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.9953. At the end of 2022 the company had a P/E ratio of -0.7143.

P/E ratio history for Onconova Therapeutics from 2013 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-0.7143-72.83%
2021-2.63-20.2%
2020-3.292233.54%
2019-0.1412-46.94%
2018-0.2661-50.12%
2017-0.533434.08%
2016-0.3978-55.99%
2015-0.9040-18.95%
2014-1.12-63.99%
2013-3.10

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
6.48-751.30%๐Ÿ‡บ๐Ÿ‡ธ USA
-2.86 187.46%๐Ÿ‡บ๐Ÿ‡ธ USA
-15.7 1,474.64%๐Ÿ‡บ๐Ÿ‡ธ USA
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
27.1-2,820.63%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.